Challenges with Point-Of-Care Tests (POCT) for Celiac Disease

Wu, H; Wallach, M; Shimoni, O

Challenges with Point-Of-Care Tests (POCT) for Celiac Disease

Wu, H Wallach, M Shimoni, O

Permalink

Publisher:: Intech Open
Publication Type:: Chapter
Citation:: Celiac Disease - From the Bench to the Clinic, 2019, pp. 1-13
Issue Date:: 2019-01-30

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (552.53 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Wu, H
dc.contributor.author	Wallach, M
dc.contributor.author	Shimoni, O https://orcid.org/0000-0001-8822-1024
dc.date.accessioned	2022-12-27T05:39:40Z
dc.date.available	2022-12-27T05:39:40Z
dc.date.issued	2019-01-30
dc.identifier.citation	Celiac Disease - From the Bench to the Clinic, 2019, pp. 1-13
dc.identifier.isbn	978-1-78985-050-5
dc.identifier.uri	http://hdl.handle.net/10453/164574
dc.description.abstract	Current screening test for celiac disease involves blood test in centralized pathology laboratories, typically performing enzyme-linked immune-sorbent assays (ELISA) to detect specific celiac disease antibodies. Most of the current available celiac disease antibody tests detect anti-gliadin (AGA), anti-endomysial (EMA), anti-transglutaminase (tTG), or deamidated gluten peptide (DGP) antibodies from serum or whole blood samples. It requires blood collection from untreated celiac patients, which is often invasive and inconvenient. There is a rapid growth in demand for noninvasive celiac tests for the early and fast diagnosis of celiac disease to help potential celiac patients obtain results and take corresponding actions. Over the last decade, several point-of-care tests (POCT) have been introduced to the market, but these tests have not been widely accepted by clinicians. Moreover, the 2009 NICE guideline CG 86 recommended that self-tests and/or POCT for celiac disease should not be used as a substitute for laboratory-based tests. Here, we provide a background on the evolution of POCT for celiac disease. We discuss general principle of operation for the known commercial kits as well as the use of various antigens and antibodies in different tests developed over the years. Finally, we discuss challenges for future research directions in celiac disease POCTs.
dc.format.extent	5
dc.language	en
dc.publisher	Intech Open
dc.relation.ispartof	Celiac Disease - From the Bench to the Clinic
dc.relation.isbasedon	10.5772/intechopen.81874
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Challenges with Point-Of-Care Tests (POCT) for Celiac Disease
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2022-12-27T05:39:39Z
pubs.place-of-publication	USA
pubs.publication-status	Published online
dc.location	USA

Abstract:

Current screening test for celiac disease involves blood test in centralized pathology laboratories, typically performing enzyme-linked immune-sorbent assays (ELISA) to detect specific celiac disease antibodies. Most of the current available celiac disease antibody tests detect anti-gliadin (AGA), anti-endomysial (EMA), anti-transglutaminase (tTG), or deamidated gluten peptide (DGP) antibodies from serum or whole blood samples. It requires blood collection from untreated celiac patients, which is often invasive and inconvenient. There is a rapid growth in demand for noninvasive celiac tests for the early and fast diagnosis of celiac disease to help potential celiac patients obtain results and take corresponding actions. Over the last decade, several point-of-care tests (POCT) have been introduced to the market, but these tests have not been widely accepted by clinicians. Moreover, the 2009 NICE guideline CG 86 recommended that self-tests and/or POCT for celiac disease should not be used as a substitute for laboratory-based tests. Here, we provide a background on the evolution of POCT for celiac disease. We discuss general principle of operation for the known commercial kits as well as the use of various antigens and antibodies in different tests developed over the years. Finally, we discuss challenges for future research directions in celiac disease POCTs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/164574